8-K: Made in USA Forms Healthcare Data Venture with Rosalind

Made in USA Inc. announced a non-binding term sheet with Rosalind, Inc. to form Rosalind Systems, Inc., a new entity focused on trusted healthcare and life sciences data infrastructure.

Summary

• Made in USA Inc. (USDW) executed a non-binding term sheet with Rosalind, Inc. on March 23, 2026, outlining a proposed transaction.
• The transaction involves the formation of Rosalind Systems, Inc., a new operating entity intended to serve as a platform for growth initiatives.
• Rosalind Systems, Inc. will operate at the intersection of healthcare, life sciences, and data infrastructure.
• The new entity plans to integrate USDW's data wallet and certification technologies with Rosalind's existing platform.
• Rosalind is expected to contribute certain platform assets and intellectual property to Rosalind Systems, Inc.
• Key focus areas for Rosalind Systems, Inc. include biopharma and biotech research, clinical and translational data, consumer health and wellness, and public health infrastructure.
• The Term Sheet is non-binding, except for customary provisions such as confidentiality and exclusivity.
• Completion of the proposed transaction is contingent upon the negotiation and execution of definitive agreements, completion of financing, and satisfaction of other customary closing conditions.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive strategic move, indicating potential for significant growth and market expansion into a critical sector, despite the non-binding nature of the initial agreement.

Positives

• Expansion of USDW's data wallet and proof-of-origin technology into the critical and high-growth healthcare and life sciences sector.
• Creation of a new operating company, Rosalind Systems, Inc., designed for scalable customer engagement and accelerated growth.
• Potential for access to capital to fund the development and expansion of the new venture.
• Integration of USDW's trusted data infrastructure (verifiable proof of origin, chain of custody, certification) with Rosalind's platform to enhance data authenticity and traceability in healthcare.
• Addresses the critical need for trusted data in an AI-driven world, particularly for medical records, research data, and clinical insights, which is essential for advancing patient care and research.

Negatives

• The term sheet is non-binding, meaning there is no guarantee that the proposed transaction will be finalized or proceed as described.
• The transaction is subject to multiple contingencies, including the negotiation and execution of definitive agreements, completion of financing, and satisfaction of customary closing conditions, any of which could prevent completion.
• There is no assurance that definitive agreements will be executed or that the proposed transaction will be consummated on the terms described or at all.

Risks

• The Term Sheet is non-binding, except for customary provisions such as confidentiality and exclusivity.
• The proposed transaction is subject to the negotiation and execution of definitive agreements.
• Completion of the transaction is contingent on the completion of financing.
• The transaction is subject to the satisfaction of other customary closing conditions.
• There can be no assurance that definitive agreements will be executed.
• There can be no assurance that the proposed transaction will be completed on the terms described in the Term Sheet or at all.

Future Outlook

The proposed transaction contemplates the integration of Made in USA Inc.'s data wallet and certification technologies with Rosalind's existing platform, intended to serve as a platform for growth initiatives at the intersection of healthcare, life sciences, and data infrastructure. Rosalind Systems, Inc. would be structured to support capital formation and expansion into areas including biopharma and biotech research, clinical and translational data, consumer health and wellness, and public health infrastructure.

Management Comments

• "This represents a foundational step in bringing trusted data infrastructure into healthcare. Truth matters—and nowhere is that more important than in the data that drives medical decisions, research, and AI. By combining our data wallet technology with Rosalind’s platform, we are creating the foundation for a new generation of certified, trustworthy data systems for research, clinical, and AI applications." Adam Reiser, CEO of Made in USA.
• "This transaction creates a path to realize our vision by bringing the Rosalind platform into the hands of more researchers across academia and biopharma. It enables them to break through the complexity of biological data and answer some of the greatest questions in human health, so we can make meaningful progress in advancing the human condition." Tim Wesselman, CEO of Rosalind.

Industry Context

StockSavvy.ai notes that this strategic initiative positions Made in USA Inc. to capitalize on the growing demand for verifiable and secure data infrastructure within the healthcare and life sciences sectors, a critical area given the increasing reliance on AI and the need for data integrity in medical research and patient care. The move aligns with broader industry trends emphasizing data trust, privacy, and interoperability, potentially giving the new entity a competitive edge in a market where data provenance is paramount.

Stakeholder Impact

• Shareholders: Potential for increased shareholder value through expansion into a high-growth sector and access to new capital, but also risk if the non-binding agreement does not materialize.
• Customers: Potential for enhanced data trust, transparency, and verifiable data solutions in healthcare and life sciences.
• Employees: Potential for new job opportunities within Rosalind Systems, Inc. and expanded roles within Made in USA Inc.
• Researchers/Academia: Access to a new platform for breaking through biological data complexity and advancing human health research.

Next Steps

• Negotiation and execution of definitive agreements for the proposed transaction.
• Completion of financing for Rosalind Systems, Inc.
• Satisfaction of customary closing conditions for the proposed transaction.
• Rosalind Systems, Inc. to build upon Rosalind's existing platform and integrate USDW's technologies.
• Expansion into biopharma and biotech research, clinical and translational data, consumer health and wellness, and public health infrastructure.

Key Dates

Recommendation

While the strategic initiative into healthcare data is promising and aligns with critical industry needs, the non-binding nature of the term sheet and the contingencies of definitive agreements and financing introduce significant uncertainty. A 'hold' recommendation is appropriate until more concrete details regarding the finalization of the transaction and financing are available, allowing investors to monitor progress without immediate commitment.

Keywords

healthcare data, life sciences, data infrastructure, Rosalind Systems, biopharma research, biotech research, clinical data, translational data, consumer health, public health, data wallet, certification technology, proof of origin, AI data, strategic partnership